EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia

  • Alzamend Neuro Inc ALZN has partnered with the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for its Phase 1/2A trial of ALZN002.
  • ALZN002 is an "active" immunotherapy product consisting of autologous dendritic cells (DCs), activated white blood cells taken from each patient that are engineered outside the body to attack Alzheimer's-related amyloid-beta proteins. 
  • "We strongly believe that the ALZN002 patient-specific immunotherapeutic vaccine has the potential of fostering tolerance to treatment for safety purposes while stimulating the immune system to reduce the brain's beta-amyloid protein burden, resulting in reduced Alzheimer's signs and symptoms," said Stephan Jackman, CEO of Alzamend.
  • The company expects to initiate the study in the first quarter of 2023."
  • Alzamend is also pursuing AL001 for bipolar disorder, major depressive disorder, and post-traumatic stress disorder. 
  • In October, Alzamend announced the addition of healthy adult subjects to its Phase 2A multiple ascending dose (MAD) study of AL001 in subjects with dementia related to Alzheimer's
  • The company anticipates reporting topline data from the Phase 2A MAD study in the second quarter of 2023.
  • Price Action: ALZN shares closed at $0.60 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMarket-Moving ExclusivesExclusivesGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!